Avoro Capital Advisors 13F: Adds $9.3M to argenx (ARGX) Stake

Avoro Capital Advisors Increases Position in argenx SE

Avoro Capital Advisors grew its investment in argenx SE ARGX by 1.0% during the period, purchasing an additional 10,000 shares to bring its total holdings to 1,000,000 shares. According to its Form 13F filing with the Securities and Exchange Commission, the fund's expanded stake carried a reported value of approximately $927.8 million at the close of the reporting window. Because 13F filings look backward at portfolio snapshots from a prior date, this report captures a past position and may not reflect the fund's current holdings today.

Share Count Details and Reported Value

Before this adjustment, Avoro Capital Advisors held 990,000 shares of the biotechnology company. The addition of 10,000 shares lifted the portfolio value significantly, given the stock's high trading price. Filings show the cost basis for the fund sits around $212.7 per share, leaving the investor with a massive unrealized gain over the long term as the stock trades much higher.

Stock Price Levels and Valuation Metrics

The company's shares trade around $927.77, resting comfortably above the 200-day moving average of $848.47 while hovering near the 50-day moving average of $941.24. Over the past year, the stock has moved between a low of $661.85 and a high of $1,072.75. The firm carries a price-to-earnings ratio of 37.7 based on trailing results, alongside strong revenue growth figures reported in recent quarters.

Wall Street Ratings and Price Targets

Financial firms have actively updated their views on the stock through the autumn months. On October 14, 2026, Wells Fargo maintained an Overweight rating while lifting its target to $1,356.0 from $1,355.0. A few days earlier on October 12, Oppenheimer kept an Outperform rating with a $1,038.0 target, down from $1,100.0. Evercore ISI Group also maintained an Outperform rating on October 9 with a $1,078.0 target, while Baird held a Neutral stance with a target of $823.0. Earlier in the autumn, Wedbush reiterated an Outperform rating with a $1,150.0 target, Morgan Stanley kept an Overweight rating with a $1,250.0 target, and UBS upgraded the stock to Buy with a $1,400.0 target in late August.

Company Focus in Specialty Therapeutics

Based in Amsterdam, argenx SE operates as a commercial-stage biopharmaceutical enterprise focused on discovering and developing treatments for various autoimmune diseases. Its core products include therapies like VYVGART and VYVGART HYTRULO, which target conditions such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company relies on an extensive clinical pipeline targeting multiple immunological disorders through strategic licensing partnerships.

Upcoming Milestones and Filing Context

Investors tracking the biotechnology developer will look toward the next scheduled earnings report on October 22, 2026, to gauge ongoing revenue momentum. Institutional disclosures such as this one remain essential for tracking how major asset managers adjust their sector exposure, though they should be viewed as historical records rather than immediate signals.